ResMed Bull Stays Positive on Margin, Earnings -- Market Talk

Dow Jones

Jun 03

0651 GMT - ResMed's bull at Citi stays positive on the breathing-tech provider following its third-quarter update. Analyst Mathieu Chevrier raises his EPS forecasts by 3.1% for fiscal 2026 and by 3.6% for fiscal 2027 on higher gross-margin expectations. He points out in a note to clients that the company has yet to see any impact from the increasing use of weight-loss drugs. Chevrier acknowledges that there is still a live debate over whether the net impact of the drugs will turn out to be negative, but notes growth in awareness of conditions such as sleep apnea could be positive. Citi raises its target price on ResMed's Australia-listed stock by 2.3% to A$45.00. Shares closed 0.6% higher at A$37.93. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

June 03, 2025 02:51 ET (06:51 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2540747982"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540747982\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540747982?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-03 14:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540747982","market":"sh","top_or_hot":-1,"title":"ResMed Bull Stays Positive on Margin, Earnings -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0651 GMT - ResMed's bull at Citi stays positive on the breathing-tech provider following its third-quarter update. Analyst Mathieu Chevrier raises his EPS forecasts by 3.1% for fiscal 2026 and by 3.6% for fiscal 2027 on higher gross-margin expectations. He points out in a note to clients that the company has yet to see any impact from the increasing use of weight-loss drugs. Chevrier acknowledges that there is still a live debate over whether the net impact of the drugs will turn out to be negative, but notes growth in awareness of conditions such as sleep apnea could be positive. Citi raises its target price on ResMed's Australia-listed stock by 2.3% to A$45.00. Shares closed 0.6% higher at A$37.93. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 03, 2025 02:51 ET (06:51 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ResMed Bull Stays Positive on Margin, Earnings -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nResMed Bull Stays Positive on Margin, Earnings -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-06-03 14:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0651 GMT - ResMed's bull at Citi stays positive on the breathing-tech provider following its third-quarter update. Analyst Mathieu Chevrier raises his EPS forecasts by 3.1% for fiscal 2026 and by 3.6% for fiscal 2027 on higher gross-margin expectations. He points out in a note to clients that the company has yet to see any impact from the increasing use of weight-loss drugs. Chevrier acknowledges that there is still a live debate over whether the net impact of the drugs will turn out to be negative, but notes growth in awareness of conditions such as sleep apnea could be positive. Citi raises its target price on ResMed's Australia-listed stock by 2.3% to A$45.00. Shares closed 0.6% higher at A$37.93. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 03, 2025 02:51 ET (06:51 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RMD","symbol_name":"瑞思迈","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2540747982","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540747982","pubTimestamp":1748933460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0651 GMT - ResMed's bull at Citi stays positive on the breathing-tech provider following its third-quarter update. Analyst Mathieu Chevrier raises his EPS forecasts by 3.1% for fiscal 2026 and by 3.6% for fiscal 2027 on higher gross-margin expectations. He points out in a note to clients that the company has yet to see any impact from the increasing use of weight-loss drugs. Chevrier acknowledges that there is still a live debate over whether the net impact of the drugs will turn out to be negative, but notes growth in awareness of conditions such as sleep apnea could be positive. Citi raises its target price on ResMed's Australia-listed stock by 2.3% to A$45.00. Shares closed 0.6% higher at A$37.93. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"RMD":"瑞思迈","RMD.AU":"Resmed DRC"},"translate_title":"瑞思迈牛市对利润率和盈利保持乐观——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD":1,"RMD.AU":0.9},"content_text":"0651 GMT - ResMed's bull at Citi stays positive on the breathing-tech provider following its third-quarter update. Analyst Mathieu Chevrier raises his EPS forecasts by 3.1% for fiscal 2026 and by 3.6% for fiscal 2027 on higher gross-margin expectations. He points out in a note to clients that the company has yet to see any impact from the increasing use of weight-loss drugs. Chevrier acknowledges that there is still a live debate over whether the net impact of the drugs will turn out to be negative, but notes growth in awareness of conditions such as sleep apnea could be positive. Citi raises its target price on ResMed's Australia-listed stock by 2.3% to A$45.00. Shares closed 0.6% higher at A$37.93. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 03, 2025 02:51 ET (06:51 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}